Geron Corporation Cash Flow Conversion Efficiency
Geron Corporation cash flow conversion efficiency. Based on the latest financial reports, Geron Corporation (GERN) has a cash flow conversion efficiency ratio of -0.072x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.83 Million) by net assets ($218.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Geron Corporation (1996–2025)
Cash flow conversion efficiency of Geron Corporation from 1996 to 2025. This chart illustrates how Geron Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Geron Corporation stock price today for real-time trading data and today's change.
Geron Corporation Cash Flow Conversion Ratio Explained
Geron Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Geron Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Geron Corporation ranked by their cash flow conversion efficiency. Also see Geron Corporation stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TPI POLENE POWER
BK:TPIPP-R
|
0.008x |
|
Zhe Jiang Kangsheng Co Ltd
SHE:002418
|
-0.053x |
|
CREOTECH INS.S.A. ZY -10
F:5OB
|
-0.259x |
|
EPC Groupe
PA:EXPL
|
0.235x |
|
Shenzhen Longtech Smart Control Co. Ltd.
SHE:300916
|
N/A |
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
-0.042x |
|
Shenzhen Sinovatio Technology Co Ltd Class A
SHE:002912
|
-0.022x |
|
Zhejiang Langdi Group Co Ltd
SHG:603726
|
0.042x |
Annual Cash Flow Conversion Efficiency for Geron Corporation (1996–2025)
The table below shows the annual cash flow conversion efficiency of Geron Corporation from 1996 to 2025. Review Geron Corporation free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $225.87 Million | $-111.04 Million | -0.492x | +36.97% |
| 2024-12-31 | $280.32 Million | $-218.62 Million | -0.780x | -15.28% |
| 2023-12-31 | $247.95 Million | $-167.74 Million | -0.677x | +57.51% |
| 2022-12-31 | $80.00 Million | $-127.38 Million | -1.592x | -110.65% |
| 2021-12-31 | $126.42 Million | $-95.56 Million | -0.756x | -139.23% |
| 2020-12-31 | $210.95 Million | $-66.65 Million | -0.316x | +2.57% |
| 2019-12-31 | $135.16 Million | $-43.83 Million | -0.324x | -174.34% |
| 2018-12-31 | $177.73 Million | $-21.01 Million | -0.118x | +40.31% |
| 2017-12-31 | $103.80 Million | $-20.56 Million | -0.198x | -31.94% |
| 2016-12-31 | $122.38 Million | $-18.37 Million | -0.150x | +11.83% |
| 2015-12-31 | $142.13 Million | $-24.20 Million | -0.170x | -338.00% |
| 2014-12-31 | $130.71 Million | $9.35 Million | 0.072x | +111.65% |
| 2013-12-31 | $59.76 Million | $-36.68 Million | -0.614x | +4.66% |
| 2012-12-31 | $85.65 Million | $-55.15 Million | -0.644x | -51.28% |
| 2011-12-31 | $146.60 Million | $-62.39 Million | -0.426x | -85.19% |
| 2010-12-31 | $192.74 Million | $-44.29 Million | -0.230x | +8.56% |
| 2009-12-31 | $172.58 Million | $-43.37 Million | -0.251x | -0.84% |
| 2008-12-31 | $168.46 Million | $-41.98 Million | -0.249x | -92.48% |
| 2007-12-31 | $205.67 Million | $-26.63 Million | -0.129x | +14.63% |
| 2006-12-31 | $173.92 Million | $-26.38 Million | -0.152x | -40.32% |
| 2005-12-31 | $190.71 Million | $-20.61 Million | -0.108x | +49.11% |
| 2004-12-31 | $122.06 Million | $-25.93 Million | -0.212x | +7.43% |
| 2003-12-31 | $106.32 Million | $-24.40 Million | -0.229x | +78.23% |
| 2002-12-31 | $29.74 Million | $-31.34 Million | -1.054x | -189.24% |
| 2001-12-31 | $61.54 Million | $-22.42 Million | -0.364x | -71.18% |
| 2000-12-31 | $63.92 Million | $-13.61 Million | -0.213x | +58.99% |
| 1999-12-31 | $26.20 Million | $-13.60 Million | -0.519x | -118.28% |
| 1998-12-31 | $32.80 Million | $-7.80 Million | -0.238x | +36.49% |
| 1997-12-31 | $21.10 Million | $-7.90 Million | -0.374x | +10.75% |
| 1996-12-31 | $23.60 Million | $-9.90 Million | -0.419x | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more